UTILITY PATENT APPLICATION TRANSMITTAL—NO FEE

	Stop Patent Application assioner for Patents			
	Sox 1450 ndria, VA 22313-1450 mitted herewith for filing is the patent application of continuation application of			
S S				5T 🚆
P P	mitted herewith for filing is the			706 1108
(<u>A</u>)	patent application of continuation application of continuation-in-part patent application of	[] [] []	divisional application of prior application information: Examiner _	151 U.S
Invent	or(s)/Applicant Identifier: James D. Marks et al.			22
For: 1	THERAPEUTIC MONOCLONAL ANTIBODIES THAT	' NEUTRAI	LIZE BOTULINUM NEUROTOXINS	
[]	For CONTINUATION or DIVISIONAL APPS only: The declaration is supplied is considered a part of the disclosure hereby incorporated by reference. The incorporation can be the submitted application parts.	re of the acc	ompanying continuation or divisional applica	ation and is
[X]	This application claims priority from each of the following and 09/144,886 Filed August 31, 1998, the disclosure(s)			t 1, 2002
[]	Please amend this application by adding the following before the first sentence: "This application is a [] continuation [] divisional [] continuation-in-part of and claims the benefit of U.S. Application No, the disclosure of which is incorporated by reference for all purposes."			
Enclos	sed are:			
[X]	98 pages of the description (including specification, claims and abstract)	[]	Request to not publish application after form	18-months
[X] [X] [X]	10 sheet(s) of [] formal [X] informal drawing(s) 01 abstract 118 number of claims	[] [X]	notification of change of [] power of attorney [] correspondence address filed in prior application Patent Application Filing Acknowledgement postcard.	
[X] [] []	03 Pages of Sequence Listing a [] signed [] unsigned Declaration a Power of Attorney	[X] []	1 extra copy of this sheet is enclose a verified statement to establish small e under 37 CFR 1.9 and 37 CFR 1.27	ed
[] [X]	a certified copy of a application cover sheet		() is enclosed () was filed in the prior appli	
[] [X]	Information Disclosure Statement under 37 CFR 1.97 Application Data Entry Sheet	[X] []	small entity status is still proper a Small Entity Status is Claimed Preliminary amendment	nd desired
	In view of the Unsigned Declaration as filed with Applicant requests deferral of the filing fee unti			
	DO <u>NOT</u> CHARGE THE F	ILING FEE	AT THIS TIME.	
		<u></u>	Ten Hent	
		Reg No	unter, J.D., Ph.D. b.: 38,498 ant's Representative	
CORRESPONDENCE ADDRESS: QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.		Attorney Docket No. 407T-895120US Client Reference No. 1998-013-2		
P.O. Box 458 Alameda, CA 94501 Telephone: (510) 337-7871 Fax: (510) 337-7877 22798		Express Mail Label No. <u>EV166670701US</u> Date of Deposit: <u>August 1, 2003</u> I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above, addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450		
1	PATENT TRADEMARK OFFICE	1_ '	Tracing and	

Tracie Brooks